Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea

Keyur B. Shah, Willem J. Kop, Robert H. Christenson, Deborah B. Diercks, Dick Kuo, Sue Henderson, Karen Hanson, Mandeep R. Mehra, Christopher R. DeFilippi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

BACKGROUND: Plasma myeloperoxidase (MPO), an inflammatory biomarker, is associated with increased mortality in patients with acute coronary syndrome or chronic left ventricular systolic dysfunction. We sought to assess the diagnostic accuracy of MPO for acute decompensated heart failure (ADHF) and its prognostic value for patients with acute dyspnea. METHODS: In a prospective, observational study conducted in 5US centers, 412 patients [mean (SD) age, 58 (14) years; 39% women] presenting with dyspnea to the emergency department were enrolled and followed for 1 year. Clinical, serum/plasma biomarker [MPO, B-type natriuretic peptide (BNP), N-terminal proBNP (NT-proBNP)], and transthoracic echocardiographic data were obtained. RESULTS: We observed no differences in MPO concentration (P = 0.07) between patients with ADHF [n = 147; median, 553 pmol/L; interquartile range (IQR), 415-738 pmol/L] and those without ADHF (n = 265; median, 576 pmol/L; IQR, 413-884 pmol/L). The diagnostic accuracy for ADHF was excellent for BNP [area under the ROC curve (AUC), 0.90; P < 0.001] and NT-proBNP (AUC, 0.90; P < 0.001) but poor for MPO (AUC, 0.46; P = 0.18). MPO appeared uncorrelated with echocardiographic measures of cardiac structure or function. The observed 1-year mortality rate was 12%. MPO concentration also appeared unrelated to mortality [hazard ratio, 1.25 (above vs below the median); 95% CI, 0.71-2.18], whereas BNP (P = 0.001) and NT-proBNP (P < 0.001) were significant predictors of mortality. MPO concentration provided no prognostic information in addition to that of BNP or NT-proBNP concentration. CONCLUSIONS: Unlike natriuretic peptides, MPO concentration was not predictive of ADHF diagnosis or 1-year mortality in a heterogeneous sample of emergency department patients with acute dyspnea.

Original languageEnglish (US)
Pages (from-to)59-67
Number of pages9
JournalClinical Chemistry
Volume55
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Dyspnea
Peroxidase
Plasmas
Brain Natriuretic Peptide
Heart Failure
Mortality
ROC Curve
Area Under Curve
Biomarkers
Hospital Emergency Service
Natriuretic Peptides
Left Ventricular Dysfunction
Acute Coronary Syndrome
Observational Studies
Hazards
Prospective Studies
pro-brain natriuretic peptide (1-76)
Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea. / Shah, Keyur B.; Kop, Willem J.; Christenson, Robert H.; Diercks, Deborah B.; Kuo, Dick; Henderson, Sue; Hanson, Karen; Mehra, Mandeep R.; DeFilippi, Christopher R.

In: Clinical Chemistry, Vol. 55, No. 1, 01.01.2009, p. 59-67.

Research output: Contribution to journalArticle

Shah, Keyur B. ; Kop, Willem J. ; Christenson, Robert H. ; Diercks, Deborah B. ; Kuo, Dick ; Henderson, Sue ; Hanson, Karen ; Mehra, Mandeep R. ; DeFilippi, Christopher R. / Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea. In: Clinical Chemistry. 2009 ; Vol. 55, No. 1. pp. 59-67.
@article{a49fee806f424cf0af6750e47e18407b,
title = "Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea",
abstract = "BACKGROUND: Plasma myeloperoxidase (MPO), an inflammatory biomarker, is associated with increased mortality in patients with acute coronary syndrome or chronic left ventricular systolic dysfunction. We sought to assess the diagnostic accuracy of MPO for acute decompensated heart failure (ADHF) and its prognostic value for patients with acute dyspnea. METHODS: In a prospective, observational study conducted in 5US centers, 412 patients [mean (SD) age, 58 (14) years; 39{\%} women] presenting with dyspnea to the emergency department were enrolled and followed for 1 year. Clinical, serum/plasma biomarker [MPO, B-type natriuretic peptide (BNP), N-terminal proBNP (NT-proBNP)], and transthoracic echocardiographic data were obtained. RESULTS: We observed no differences in MPO concentration (P = 0.07) between patients with ADHF [n = 147; median, 553 pmol/L; interquartile range (IQR), 415-738 pmol/L] and those without ADHF (n = 265; median, 576 pmol/L; IQR, 413-884 pmol/L). The diagnostic accuracy for ADHF was excellent for BNP [area under the ROC curve (AUC), 0.90; P < 0.001] and NT-proBNP (AUC, 0.90; P < 0.001) but poor for MPO (AUC, 0.46; P = 0.18). MPO appeared uncorrelated with echocardiographic measures of cardiac structure or function. The observed 1-year mortality rate was 12{\%}. MPO concentration also appeared unrelated to mortality [hazard ratio, 1.25 (above vs below the median); 95{\%} CI, 0.71-2.18], whereas BNP (P = 0.001) and NT-proBNP (P < 0.001) were significant predictors of mortality. MPO concentration provided no prognostic information in addition to that of BNP or NT-proBNP concentration. CONCLUSIONS: Unlike natriuretic peptides, MPO concentration was not predictive of ADHF diagnosis or 1-year mortality in a heterogeneous sample of emergency department patients with acute dyspnea.",
author = "Shah, {Keyur B.} and Kop, {Willem J.} and Christenson, {Robert H.} and Diercks, {Deborah B.} and Dick Kuo and Sue Henderson and Karen Hanson and Mehra, {Mandeep R.} and DeFilippi, {Christopher R.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1373/clinchem.2008.108159",
language = "English (US)",
volume = "55",
pages = "59--67",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "1",

}

TY - JOUR

T1 - Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea

AU - Shah, Keyur B.

AU - Kop, Willem J.

AU - Christenson, Robert H.

AU - Diercks, Deborah B.

AU - Kuo, Dick

AU - Henderson, Sue

AU - Hanson, Karen

AU - Mehra, Mandeep R.

AU - DeFilippi, Christopher R.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - BACKGROUND: Plasma myeloperoxidase (MPO), an inflammatory biomarker, is associated with increased mortality in patients with acute coronary syndrome or chronic left ventricular systolic dysfunction. We sought to assess the diagnostic accuracy of MPO for acute decompensated heart failure (ADHF) and its prognostic value for patients with acute dyspnea. METHODS: In a prospective, observational study conducted in 5US centers, 412 patients [mean (SD) age, 58 (14) years; 39% women] presenting with dyspnea to the emergency department were enrolled and followed for 1 year. Clinical, serum/plasma biomarker [MPO, B-type natriuretic peptide (BNP), N-terminal proBNP (NT-proBNP)], and transthoracic echocardiographic data were obtained. RESULTS: We observed no differences in MPO concentration (P = 0.07) between patients with ADHF [n = 147; median, 553 pmol/L; interquartile range (IQR), 415-738 pmol/L] and those without ADHF (n = 265; median, 576 pmol/L; IQR, 413-884 pmol/L). The diagnostic accuracy for ADHF was excellent for BNP [area under the ROC curve (AUC), 0.90; P < 0.001] and NT-proBNP (AUC, 0.90; P < 0.001) but poor for MPO (AUC, 0.46; P = 0.18). MPO appeared uncorrelated with echocardiographic measures of cardiac structure or function. The observed 1-year mortality rate was 12%. MPO concentration also appeared unrelated to mortality [hazard ratio, 1.25 (above vs below the median); 95% CI, 0.71-2.18], whereas BNP (P = 0.001) and NT-proBNP (P < 0.001) were significant predictors of mortality. MPO concentration provided no prognostic information in addition to that of BNP or NT-proBNP concentration. CONCLUSIONS: Unlike natriuretic peptides, MPO concentration was not predictive of ADHF diagnosis or 1-year mortality in a heterogeneous sample of emergency department patients with acute dyspnea.

AB - BACKGROUND: Plasma myeloperoxidase (MPO), an inflammatory biomarker, is associated with increased mortality in patients with acute coronary syndrome or chronic left ventricular systolic dysfunction. We sought to assess the diagnostic accuracy of MPO for acute decompensated heart failure (ADHF) and its prognostic value for patients with acute dyspnea. METHODS: In a prospective, observational study conducted in 5US centers, 412 patients [mean (SD) age, 58 (14) years; 39% women] presenting with dyspnea to the emergency department were enrolled and followed for 1 year. Clinical, serum/plasma biomarker [MPO, B-type natriuretic peptide (BNP), N-terminal proBNP (NT-proBNP)], and transthoracic echocardiographic data were obtained. RESULTS: We observed no differences in MPO concentration (P = 0.07) between patients with ADHF [n = 147; median, 553 pmol/L; interquartile range (IQR), 415-738 pmol/L] and those without ADHF (n = 265; median, 576 pmol/L; IQR, 413-884 pmol/L). The diagnostic accuracy for ADHF was excellent for BNP [area under the ROC curve (AUC), 0.90; P < 0.001] and NT-proBNP (AUC, 0.90; P < 0.001) but poor for MPO (AUC, 0.46; P = 0.18). MPO appeared uncorrelated with echocardiographic measures of cardiac structure or function. The observed 1-year mortality rate was 12%. MPO concentration also appeared unrelated to mortality [hazard ratio, 1.25 (above vs below the median); 95% CI, 0.71-2.18], whereas BNP (P = 0.001) and NT-proBNP (P < 0.001) were significant predictors of mortality. MPO concentration provided no prognostic information in addition to that of BNP or NT-proBNP concentration. CONCLUSIONS: Unlike natriuretic peptides, MPO concentration was not predictive of ADHF diagnosis or 1-year mortality in a heterogeneous sample of emergency department patients with acute dyspnea.

UR - http://www.scopus.com/inward/record.url?scp=58149263078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149263078&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2008.108159

DO - 10.1373/clinchem.2008.108159

M3 - Article

C2 - 18988754

AN - SCOPUS:58149263078

VL - 55

SP - 59

EP - 67

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 1

ER -